Our Company
OUR PATIENT ACCESS PHILOSOPHY
Our Commitment to Patients and Partners
At Alnylam, we believe that the discovery and development of RNAi therapeutics is only the first step. It is our responsibility to be as innovative delivering new medicines for patients as we are in the lab. At the core of this belief is our Patient Access Philosophy, which guides our approach to access, affordability and outcomes as they relate to our therapies, and the therapeutic areas we serve.
Our Patient Access Philosophy was created in 2017, before our first medicine was even approved, as we prepared to become a commercial-stage biopharmaceutical company. These principles guide the decisions we make and how we engage with patients and other stakeholders who play a role in access and affordability.
At Alnylam, we know that medical and scientific innovation are only worth while if the people who can benefit from life-changing therapies have access to them. Despite living in an age of medicinal breakthroughs, patients are too often unable to receive the treatment they need due to their location, their insurance, or other obstacles. We are committed to working with partners around the world to ensure our drugs are accessible and affordable to all, because no patient should have to wait for hope. - Yvonne Greenstreet, MBChB, CEO of Alnylam